161 related articles for article (PubMed ID: 38312795)
1. Iptacopan in Idiopathic Immune Complex-Mediated Membranoproliferative Glomerulonephritis: Protocol of the APPARENT Multicenter, Randomized Phase 3 Study.
Vivarelli M; Bomback AS; Meier M; Wang Y; Webb NJA; Veldandi UK; Smith RJH; Kavanagh D
Kidney Int Rep; 2024 Jan; 9(1):64-72. PubMed ID: 38312795
[TBL] [Abstract][Full Text] [Related]
2. Alternative Complement Pathway Inhibition With Iptacopan for the Treatment of C3 Glomerulopathy-Study Design of the APPEAR-C3G Trial.
Bomback AS; Kavanagh D; Vivarelli M; Meier M; Wang Y; Webb NJA; Trapani AJ; Smith RJH
Kidney Int Rep; 2022 Oct; 7(10):2150-2159. PubMed ID: 36217526
[TBL] [Abstract][Full Text] [Related]
3. Targeting the Alternative Complement Pathway With Iptacopan to Treat IgA Nephropathy: Design and Rationale of the APPLAUSE-IgAN Study.
Rizk DV; Rovin BH; Zhang H; Kashihara N; Maes B; Trimarchi H; Perkovic V; Meier M; Kollins D; Papachristofi O; Charney A; Barratt J
Kidney Int Rep; 2023 May; 8(5):968-979. PubMed ID: 37180505
[TBL] [Abstract][Full Text] [Related]
4. Results of a randomized double-blind placebo-controlled Phase 2 study propose iptacopan as an alternative complement pathway inhibitor for IgA nephropathy.
Zhang H; Rizk DV; Perkovic V; Maes B; Kashihara N; Rovin B; Trimarchi H; Sprangers B; Meier M; Kollins D; Papachristofi O; Milojevic J; Junge G; Nidamarthy PK; Charney A; Barratt J
Kidney Int; 2024 Jan; 105(1):189-199. PubMed ID: 37914086
[TBL] [Abstract][Full Text] [Related]
5. Design and Rationale of the APPELHUS Phase 3 Open-Label Study of Factor B Inhibitor Iptacopan for Atypical Hemolytic Uremic Syndrome.
Kavanagh D; Greenbaum LA; Bagga A; Karki RG; Chen CW; Vasudevan S; Charney A; Dahlke M; Fakhouri F
Kidney Int Rep; 2023 Jul; 8(7):1332-1341. PubMed ID: 37441479
[TBL] [Abstract][Full Text] [Related]
6. C5 Convertase Blockade in Membranoproliferative Glomerulonephritis: A Single-Arm Clinical Trial.
Ruggenenti P; Daina E; Gennarini A; Carrara C; Gamba S; Noris M; Rubis N; Peraro F; Gaspari F; Pasini A; Rigotti A; Lerchner RM; Santoro D; Pisani A; Pasi A; Remuzzi G;
Am J Kidney Dis; 2019 Aug; 74(2):224-238. PubMed ID: 30929851
[TBL] [Abstract][Full Text] [Related]
7. Morphofunctional Effects of C5 Convertase Blockade in Immune Complex-Mediated Membranoproliferative Glomerulonephritis: Report of Two Cases with Evidence of Terminal Complement Activation.
Carrara C; Podestà MA; Abbate M; Rizzo P; Piras R; Alberti M; Daina E; Ruggenenti P; Remuzzi G;
Nephron; 2020; 144(4):195-203. PubMed ID: 32050203
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.
Wong E; Nester C; Cavero T; Karras A; Le Quintrec M; Lightstone L; Eisenberger U; Soler MJ; Kavanagh D; Daina E; Praga M; Medjeral-Thomas NR; Gäckler A; Garcia-Carro C; Biondani A; Chaperon F; Kulmatycki K; Milojevic J; Webb NJA; Nidamarthy PK; Junge G; Remuzzi G
Kidney Int Rep; 2023 Dec; 8(12):2754-2764. PubMed ID: 38106570
[TBL] [Abstract][Full Text] [Related]
9. Clinical Outcomes of Patients with C3G or IC-MPGN Treated with the Factor D Inhibitor Danicopan: Final Results from Two Phase 2 Studies.
Nester C; Appel GB; Bomback AS; Bouman KP; Cook HT; Daina E; Dixon BP; Rice K; Najafian N; Hui J; Podos SD; Langman CB; Lightstone L; Parikh SV; Pickering MC; Sperati CJ; Trachtman H; Tumlin J; de Vries AP; Wetzels JFM; Remuzzi G
Am J Nephrol; 2022; 53(10):687-700. PubMed ID: 36423588
[TBL] [Abstract][Full Text] [Related]
10. Autoimmune abnormalities of the alternative complement pathway in membranoproliferative glomerulonephritis and C3 glomerulopathy.
Noris M; Donadelli R; Remuzzi G
Pediatr Nephrol; 2019 Aug; 34(8):1311-1323. PubMed ID: 29948306
[TBL] [Abstract][Full Text] [Related]
11. Membranoproliferative glomerulonephritis: no longer the same disease and may need very different treatment.
Noris M; Daina E; Remuzzi G
Nephrol Dial Transplant; 2023 Feb; 38(2):283-290. PubMed ID: 34596686
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic and Prognostic Comparison of Immune-Complex-Mediated Membranoproliferative Glomerulonephritis and C3 Glomerulopathy.
Kovala M; Seppälä M; Räisänen-Sokolowski A; Meri S; Honkanen E; Kaartinen K
Cells; 2023 Feb; 12(5):. PubMed ID: 36899849
[TBL] [Abstract][Full Text] [Related]
13. Long-Term Outcomes of C3 Glomerulopathy and Immune-Complex Membranoproliferative Glomerulonephritis in Children.
Kirpalani A; Jawa N; Smoyer WE; Licht C;
Kidney Int Rep; 2020 Dec; 5(12):2313-2324. PubMed ID: 33305125
[TBL] [Abstract][Full Text] [Related]
14. Outcome of membranoproliferative glomerulonephritis and C3-glomerulopathy in children and adolescents.
Holle J; Berenberg-Goßler L; Wu K; Beringer O; Kropp F; Müller D; Thumfart J
Pediatr Nephrol; 2018 Dec; 33(12):2289-2298. PubMed ID: 30238151
[TBL] [Abstract][Full Text] [Related]
15. [Diagnosis and treatment of glomerular diseases with a membranoproliferative glomerulonephritis (MPGN) pattern of injury].
Rudnicki M; Windpessl M; Eller K; Odler B; Gauckler P; Neumann I; Zitt E; Regele H; Kronbichler A; Lhotta K; Säemann MD
Wien Klin Wochenschr; 2023 Aug; 135(Suppl 5):688-695. PubMed ID: 37728653
[TBL] [Abstract][Full Text] [Related]
16. [Familial membranoproliferative glomerulonephritis].
Bogdanović RM; Dimitrjević JZ; Nikolić VN; Ognjanović MV; Rodić BD; Slavković BV
Srp Arh Celok Lek; 1999; 127(5-6):163-71. PubMed ID: 10500423
[TBL] [Abstract][Full Text] [Related]
17. Characteristics of membranoproliferative glomerulonephritis based on a new classification at a single center.
Nakano M; Karasawa K; Moriyama T; Uchida K; Nitta K
Clin Exp Nephrol; 2019 Jun; 23(6):852-858. PubMed ID: 30854618
[TBL] [Abstract][Full Text] [Related]
18. Addition of iptacopan, an oral factor B inhibitor, to eculizumab in patients with paroxysmal nocturnal haemoglobinuria and active haemolysis: an open-label, single-arm, phase 2, proof-of-concept trial.
Risitano AM; Röth A; Soret J; Frieri C; de Fontbrune FS; Marano L; Alashkar F; Benajiba L; Marotta S; Rozenberg I; Milojevic J; End P; Nidamarthy PK; Junge G; Peffault de Latour R
Lancet Haematol; 2021 May; 8(5):e344-e354. PubMed ID: 33765419
[TBL] [Abstract][Full Text] [Related]
19.
Piras R; Breno M; Valoti E; Alberti M; Iatropoulos P; Mele C; Bresin E; Donadelli R; Cuccarolo P; Smith RJH; Benigni A; Remuzzi G; Noris M
Front Genet; 2021; 12():670727. PubMed ID: 34211499
[TBL] [Abstract][Full Text] [Related]
20. Membranoproliferative glomerulonephritis in Russian population.
Dobronravov VA; Smirnov AV
Ter Arkh; 2018 Dec; 90(12):39-47. PubMed ID: 30701832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
